MSAT Data Expert (Biologics)
Takeda
Summary
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company founded in 1781 and incorporated in 1925. As one of the world's top 20 largest pharmaceutical companies by revenue and the third largest in Asia, Takeda specializes in developing and commercializing innovative medicines across several therapeutic areas including oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines. With approximately 49,095 employees globally, the company operates research and development centers, manufacturing facilities, and commercial operations across 39 U.S. states and numerous countries worldwide. Takeda maintains dual headquarters in Tokyo and Osaka, Japan, with significant operations in Cambridge, Massachusetts, where it serves as the largest life sciences employer in the state. The company's patient-focused approach is guided by its Takeda-ism values of Integrity, Fairness, Honesty, and Perseverance, emphasizing a commitment to delivering life-transforming treatments while advancing sustainable healthcare solutions. Takeda's extensive portfolio includes both innovative biologics and small molecule drugs, supported by strategic acquisitions and partnerships that have expanded its capabilities in areas such as immuno-oncology and rare disease treatments.
Job description
About the role
- Design, implement, and maintain CMC data standards, taxonomies, and ontologies for the biologics modality.
- Ensure high-quality, contextualized, and analysis-ready CMC process data to enable MSAT and manufacturing use cases.
- Translate global CMC data strategy into practical implementation, including SOPs and business rules.
- Act as a subject matter expert (SME) in CMC data for biologics, supporting governance and integration.
How you will contribute
- Develop and maintain CMC data taxonomies, ontologies, and metadata models for biologics.
- Implement CMC data models and business rules across systems.
- Ensure data quality, consistency, and integrity.
- Support SOPs, standards, and job aids.
- Collaborate with MSAT teams for proper data capture and usage.
- Enable CMC data integration across systems and sites.
- Provide CMC data expertise to analytics and modelling initiatives.
- Act as CMC data steward for specific domains.
- Support GxP compliance and inspections.
- Contribute to knowledge sharing and continuous improvement.
What you bring to Takeda
- Advanced degree in STEM.
- 5 years in pharma/biotech with CMC or MSAT experience in biologics.
- Experience in data modeling or governance.
- GxP environment experience.
- Strong collaboration skills.
Requirements
- Advanced degree in STEM
- 5 years in pharma/biotech with CMC or MSAT experience in biologics
- Experience in data modeling or governance
- GxP environment experience
- Strong collaboration skills
Company overview
Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company founded in 1781 and incorporated in 1925. As one of the world's top 20 largest pharmaceutical companies by revenue and the third largest in Asia, Takeda specializes in developing and commercializing innovative medicines across several therapeutic areas including oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines. With approximately 49,095 employees globally, the company operates research and development centers, manufacturing facilities, and commercial operations across 39 U.S. states and numerous countries worldwide. Takeda maintains dual headquarters in Tokyo and Osaka, Japan, with significant operations in Cambridge, Massachusetts, where it serves as the largest life sciences employer in the state. The company's patient-focused approach is guided by its Takeda-ism values of Integrity, Fairness, Honesty, and Perseverance, emphasizing a commitment to delivering life-transforming treatments while advancing sustainable healthcare solutions. Takeda's extensive portfolio includes both innovative biologics and small molecule drugs, supported by strategic acquisitions and partnerships that have expanded its capabilities in areas such as immuno-oncology and rare disease treatments.